Ventyx Biosciences, Inc.

Ventyx Biosciences, Inc. (VTYX) priced its initial public offering on Oct 21, 2021 at $16.00 per share, within its $15.00–$17.00 range, raising $151.6M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $782.9M. Jefferies was lead-left underwriter, joined by Evercore ISI and Piper Sandler. Wilson Sonsini advised the company and Cooley advised the underwriters.

Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company developing therapies for inflammatory and autoimmune diseases. Its lead candidate, VTX958, is an oral, selective TYK2 inhibitor designed to avoid inhibiting other JAK isoforms.

Status

IPO

Ticker

VTYX

Exchange

Nasdaq Global Select

Priced

Oct 21, 2021

IPO price

$16.00

Price range

$15.00–$17.00

Raised

$151.6M

Market cap at IPO price

$782.9M

First filed

Sep 29, 2021

Underwriters

Jefferies, Evercore ISI and Piper Sandler

Company counsel

Wilson Sonsini

Underwriters' counsel

Cooley

Sector

Biotech & pharma

Country / state

CA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.